|
Match
|
Document |
Document Title |
|
|
US20080193460 |
CHIMERIC, HUMAN AND HUMANIZED ANTI-CSAP MONOCLONAL ANTIBODIES
The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers,...
|
|
|
US20080118513 |
Treatment of immune disorders with antibodies to costimulating polypeptide of T cells
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal...
|
|
|
US20080118510 |
VEGF-RELATED PROTEIN
A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third...
|
|
|
US20080118508 |
Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an...
|
|
|
US20080107656 |
IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF
The present invention relates generally to a method of eliciting or otherwise inducing an immune response to a Plasmodium microorganism and compositions for use therein. More particularly, the...
|
|
|
US20080089891 |
Cancerous disease modifying antibodies
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer...
|
|
|
US20080089890 |
METHODS OF POLYPEPTIDE PRODUCTION
The present invention relates to methods and compositions for adenovirus mediated production of a polypeptide of interest in replication non-permissive cells. The invention also relates to...
|
|
|
US20080089889 |
Novel Bone Metastasis Marker Peptide and Method of Diagnosing Bone Metastasis by Using the Same
It is intended to provide: a peptide which shows an increase in the expression amount in the serum of a cancer patient with the passage of time before the onset of bone metastasis and after the...
|
|
|
US20080089861 |
Combination therapy for treatment of demyelinating conditions
The invention provides compositions and methods for treating autoimmune diseases such as multiple sclerosis. The compositions include a combination of an NMDA Receptor antagonist, such as memantine...
|
|
|
US20080081040 |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth...
|
|
|
US20080075726 |
Anti-IL-6 monoclonal antibodies and uses thereof
The present invention provides novel monoclonal antibodies that bind specifically to IL-6. The antibodies of the invention comprise a variable heavy chain (VH) region selected from any of the VH...
|
|
|
US20080075725 |
Novel Immunointeractive Molecules and uses Thereof
The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to...
|
|
|
US20080075659 |
Proteins with high immunoreactivity and method for their production
The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced...
|
|
|
US20080069815 |
ANTI-OSTEOPONTIN ANTIBODY AND USE THEREOF
An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR...
|
|
|
US20080069795 |
Amelioration of Drug-Induced Toxicity
Kidney toxicity which is induced by cisplatin and other therapeutic and diagnostic agents, limits the effectiveness of the therapy or diagnosis. Modulation or depletion of T cells ameliorates the...
|
|
|
US20080063600 |
Diagnostics And Therapeutics For Transmissible Spongiform Encephalopathy And Methods For The Manufacture Of Non-Infective Blood Products And Tissued Derived Products
B-cells have been identified as being the crucial carriers of infectivity in the spread of transmissible spongiform encephalopathy within an infected organism. In a second step, B-cells may infect...
|
|
|
US20080057069 |
Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue
This invention provides a method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue in a subject comprising administering to the subject an agent that inhibits...
|
|
|
US20080057068 |
SARMS and method of use thereof
This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, muscle wasting diseases and/or disorders, bone-related...
|
|
|
US20080057061 |
Method of Treating Diseases and Disorders
We have discovered that targeting carbohydrates on cell, or viral particle surfaces, such as using antibodies against such carbohydrates also called glycans provide a new tool to treat diseases and...
|
|
|
US20080057059 |
Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors
The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a protein S inhibitor, and the use thereof for treating bleeding episodes.
|
|
|
US20080050386 |
Novel proteins, gene encoding the same and method of utilization thereof
The present invention provides, as a gene encoding an antigen recognized by G-CSF-inducing antibodies, a gene encoding: (a) a protein having the amino acid sequence listed as SEQ ID NO:2 of the...
|
|
|
US20080050385 |
TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY
The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The...
|
|
|
US20080050384 |
Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds,...
|
|
|
US20080050383 |
IMMUNOTHERAPY FOR CLEARING PATHOLOGICAL TAU CONFORMERS
The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies...
|
|
|
US20080050372 |
INHIBITION OF ALPHA-2 HS GLYCOPROTEIN (AHSG/FETUIN) IN OBESITY AND INSULIN CONTROL OF GLUCOSE HOMEOSTASIS
α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances...
|
|
|
US20080050369 |
Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cells
Activation of smooth muscle cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the smooth muscle cells with an anti-T-BAM (CD40L) antibody capable of inhibiting the...
|
|
|
US20080044382 |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive...
|
|
|
US20080044378 |
Methods and Compositions for Protein Production Using Adenoviral Vectors
The present invention provides methods and compositions for recombinant protein production through replication-defective adenoviral vector infection of non-trans-complementation cell lines. Thus,...
|
|
|
US20080038271 |
Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
The present application describes extending survival in a cancer patient, where the patient is producing an elevated level of EGF or TGF-alpha, by treating the patient with a HER dimerization...
|
|
|
US20080038270 |
Antibody Specific For A Chondroitin Sulphate Epitope
An antibody specific for a chondroitin sulphate epitope is described, as is a hybridoma cell line which produces such an antibody. The antibody is useful in the diagnosis and treatment of...
|
|
|
US20080038250 |
Profilin and related immunomodulatory ligands
The invention provides profilin-related immunomodulatory polypeptides and toll-like receptor agonists, as well as related pharmaceutical compositions and methods of treatment, useful for treating...
|
|
|
US20080031879 |
Pharmaceutical composition containing inhibitors of interferon-gamma
|
|
|
US20080025985 |
Method of treating a pathological syndrome and a pharmaceutical agent
A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated...
|
|
|
US20080019970 |
METHODS FOR PREVENTING, POSTPONING OR IMPROVING THE OUTCOME OF SPINAL DEVICE AND FUSION PROCEDURES
Methods for identifying subjects who could benefit therapeutically from administration of a high specificity cytokine inhibitor are provided. Subjects that are identified include those that are...
|
|
|
US20080019910 |
Cancer Treatment and Cancer Treatment Efficacy Prediction by Blocking and Detecting Protease Inhibitors
Disclosed is a method for improving cancer therapy that relies on induction of apoptosis in malignant cells. It has been found that docking of protease inhibitors PAI-1 and TIMP-1 renders malignant...
|
|
|
US20080014199 |
Assessing Cancer And Vimentin
This document provide methods and materials related to determining whether or not a mammal (e.g., a human) having cancer (e.g., leukemia) is susceptible to a poor outcome. For example, this...
|
|
|
US20080014198 |
Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels
Agents that perturb the EGF signaling pathway and that are known to be useful in the treatment of cancer are found also to result in increased expression of the protein clusterin. Since clusterin...
|
|
|
US20080014195 |
Antagonists Of Myelin-Associated Glycoprotein And Their Use In The Treatment And/Or Prevention Of Neurological Diseases
A method of treatment or prophylaxis of stroke and other neurological diseases in a human which comprises administering an effective amount of a MAG antagonist or anti-MAG antibody including...
|
|
|
US20080014194 |
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such...
|